Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia.

Min Zhou; Xinshan Sha; Huiying Qiu; Guangsheng HE; Yang XU; Jiannong Cen; Jinlan Pan; Suning Chen; Aining Sun; Ri Zhang; Depei WU

Return

Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia.

Author: Min ZHOU ¹ ; Xinshan SHA ¹ ; Huiying QIU ¹ ; Guangsheng HE ¹ ; Yang XU ¹ ; Jiannong CEN ¹ ; Jinlan PAN ¹ ; Suning CHEN ¹ ; Aining SUN ¹ ; Ri ZHANG ¹ ; Depei WU ¹
Author Information

1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China.
Publication Type:Journal Article
MeSH: Adolescent; Adult; Aged; Benzamides; therapeutic use; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; therapy; Male; Middle Aged; Piperazines; therapeutic use; Protein Kinase Inhibitors; therapeutic use; Pyrimidines; therapeutic use; Retrospective Studies; Transplantation, Homologous; Young Adult
From: Chinese Journal of Hematology 2014;35(2):126-128
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo compare the curative effect of imatinib and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the treatment of chronic myeloid leukemia (CML).
METHODS292 CML patients received imatinib, and 141 patients underwent allo-HSCT. The clinical data of these patients were retrospectively analyzed to compare event- free survival (EFS) and overall survival (OS) between these two groups of patients in chronic and advanced (including accelerate and blast) phases.
RESULTS(1) EFS, OS, expected 5- year EFS and OS of imatinib group (278 patients in chronic phase) were all statistically higher than of allo-HSCT group (120 patients in chronic phase) (88.5% vs 70.0%, 93.2% vs 80.0%, 84.0% vs 75.0% and 92.0% vs 79.0%, respectively, all P values < 0.01). (2) EFS and OS of imatinib group (14 patients in accelerate and blast phases) were 42.9% and 42.9%, respectively. Meanwhile EFS and OS of allo-HSCT group (21 patients in accelerate and blast phases) were 47.6% and 57.1%, respectively. There were no significant differences in terms of EFS and OS between the two groups (P values>0.05).
CONCLUSIONEFS and OS of imatinib group were significantly higher than of allo-HSCT group for CML patients of in chronic phase. Imatinib and allo-HSCT had the similar efficacy for CML patients in accelerate and blast phases.